Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPRONESTYL-SR (procainamide hydrochloride) by Bristol Myers Squibb is clinical pharmacology procainamide (pa) increases the effective refractory period of the atria, and to a lesser extent the bundle of his-purkinje system and ventricles of the heart. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1981.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Procainamide (PA) increases the effective refractory period of the atria, and to a lesser extent the bundle of His-Purkinje system and ventricles of the heart. It reduces impulse conduction velocity in the atria, His-Purkinje fibers, and ventricular muscle, but has variable…
Worked on PRONESTYL-SR at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo